This report was first published by Endpoints News. To see the original version, click here
The money continues to flow for private obesity and MASH drug developers.
The latest pool of capital is headed to a Shanghai biotech called Cascade Pharmaceuticals. The company disclosed a nearly 500 million yuan (about $72 million) financing round via an announcement on WeChat this week. The biotech, founded in December 2017, previously disclosed a 140 million yuan round in August 2023 and two “nearly” 100 million yuan rounds in 2020 and 2022.
您已阅读17%（537字），剩余83%（2633字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。